Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells
- PMID: 12902485
- DOI: 10.4049/jimmunol.171.4.1844
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells
Abstract
The goal of adoptive T cell therapy in cancer is to provide effective antitumor immunity by transfer of selected populations of tumor Ag-specific T cells. Transfer of T cells with high TCR avidity is critical for in vivo efficacy. In this study, we demonstrate that fluorescent peptide/MHC class I multimeric complexes incorporating mutations in the alpha3 domain (D227K/T228A) that abrogate binding to the CD8 coreceptor can be used to selectively isolate tumor Ag-specific T cells of high functional avidity from both in vitro expanded and ex vivo T cell populations. Sorting, cloning, and expansion of alpha3 domain mutant multimer-positive CD8 T cells enabled rapid selection of high avidity tumor-reactive T cell clones. Our results are relevant for ex vivo identification and isolation of T cells with potent antitumor activity for adoptive T cell therapy.
Similar articles
-
Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate.J Immunol. 2003 May 15;170(10):5110-7. doi: 10.4049/jimmunol.170.10.5110. J Immunol. 2003. PMID: 12734357
-
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.J Immunol. 1999 Feb 15;162(4):2227-34. J Immunol. 1999. PMID: 9973498
-
Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.J Immunol. 2002 Apr 15;168(8):4231-40. doi: 10.4049/jimmunol.168.8.4231. J Immunol. 2002. PMID: 11937585
-
Multimer technologies for detection and adoptive transfer of antigen-specific T cells.Cancer Immunol Immunother. 2010 Feb;59(2):195-202. doi: 10.1007/s00262-009-0778-4. Epub 2009 Oct 22. Cancer Immunol Immunother. 2010. PMID: 19847424 Free PMC article. Review.
-
High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.Immunol Res. 2005;31(1):13-24. doi: 10.1385/IR:31:1:13. Immunol Res. 2005. PMID: 15591619 Review.
Cited by
-
Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.Immunol Res. 2006;34(1):67-87. doi: 10.1385/IR:34:1:67. Immunol Res. 2006. PMID: 16720899
-
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15154-9. doi: 10.1073/pnas.0406649101. Epub 2004 Oct 11. Proc Natl Acad Sci U S A. 2004. PMID: 15477598 Free PMC article.
-
Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.Front Immunol. 2013 Jul 30;4:218. doi: 10.3389/fimmu.2013.00218. eCollection 2013. Front Immunol. 2013. PMID: 23908656 Free PMC article.
-
High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.Front Immunol. 2020 Jan 8;10:3016. doi: 10.3389/fimmu.2019.03016. eCollection 2019. Front Immunol. 2020. PMID: 31969886 Free PMC article.
-
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface.J Biol Chem. 2005 Jul 29;280(30):27491-501. doi: 10.1074/jbc.M500555200. Epub 2005 Apr 18. J Biol Chem. 2005. PMID: 15837791 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
